GENOMIC TESTING

With genetic screening for mutations and biomarkers gaining more prevalence in diagnosing and treating cancer, genetic testing and counseling for patients with prostate cancer is becoming a pressing concept that urologists need to better understand. At the 2017 LUGPA Annual Meeting, Leonard Gomella, MD, gave a presentation stressing the importance of integrating genetic testing into clinical practice.

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital, director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, discusses when to order next-generation sequencing for a patient with metastatic colon cancer.

As the breast cancer genome continues to be unraveled, a host of new targetable alterations outside of HER2 and the estrogen receptor are beginning to emerge, providing the exciting potential for development of new therapies.

Advancements made in the field of molecular genetics for patients with myeloproliferative neoplasms may be increasingly incorporated into treatment decisions, according to a presentation by Ann Mullally, MD, during the 2017 SOHO Annual Meeting.

Comprehensive genomic testing is not yet widespread, but a French study presented at the 2017 ASCO Annual Meeting suggested that DNA profiling can be of important value in advancing personalized medicine. Patients who received molecularly targeted agents based on genomic profiles had longer 3-year and 5-year overall survival than those who did not.

Siddhartha Devarakonda, MD, highlights the importance of testing for molecular markers, some of the rarer mutations, and what work lies ahead for the field of NSCLC.

During the Society for Gynecologic Oncology 48th Annual Meeting in National Harbor, Maryland, Jubilee Brown, MD, offered advice on where to access this counseling and why it is so important for women with ovarian cancer to advocate for genetic testing. 

The recommendation for molecular testing made in the second revision of the 2016 guidelines on bladder cancer from the National Comprehensive Cancer Network (NCCN) could make a considerable difference in increasing the amount of trials and targeted therapies in the long run for subtypes of patients with bladder cancer.

The FDA has released 2 draft guidances regarding the use of next-generation sequencing-based tests.

Multigene panel testing may uncover new risks in breast cancer and ovarian cancer.

Gregory E. Idos, MD, discusses a study examining the yield of multiplex panel testing compared with expert opinion and validated prediction models.

Neratinib, an experimental TKI being developed for breast cancer, achieved a 36% clinical benefit rate in a phase II trial, according to a poster presented June 5, 2016 at the ASCO Annual Meeting in Chicago.

BRAF mutation testing has become an essential tool in the diagnostic workup and management of patients with advanced melanoma.

This week's best content includes oral HPV's role in SCCHN, a full clinical hold for pacritnib, immunotherapies in head and neck cancer, and more.

This is the "Conclusion and References" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Emerging Therapies" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Emerging Biomarkers" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Prognosis and Treatment" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Current Treatment Strategies" section of the current issue of Evolving Paradigms In Bladder Cancer.

This is the "Introduction" section of the current issue of Evolving Paradigms In Bladder Cancer.

A new method to elucidate the clonal relationship between tumors used tissues and clinical details from patients with contralateral breast cancer, and for the first time, next-generation sequencing.

Julie Gralow, MD, Professor, Medical Oncology Division, University of Washington School of Medicine, talks about the importance of women knowing which genetic tests they�ve previously had done for breast cancer.

Daniel S. Oh, MD, assistant professor of surgery, University of Southern California, Keck School of Medicine, discusses myPlan genetic testing in patients with lung cancer.

Sonidegib (Odomzo) was approved by the EC for the treatment of patients who have locally advanced basal cell carcinoma (laBCC) and are not amenable to curative surgery or radiation therapy.